LATEST ALERTS
While not related solely or specifically to tobacco products, novel or otherwise, moves in both the EU and the US towards environmental regulations are likely to have a major impact on the sector
What the US Food and Drug Administration (FDA)’s proposed new rule on manufacturing practices for tobacco products really means is an intriguing question. What can it tell us about the agency’s vision for future regulation?
Tamarind Intelligence data continues to be an invaluable tool used by governments and NGOs around the world, contributing to a wide number of government and supra-national projects
Is Dave Dobbins’s switch from COO of the Truth Initiative to a role with a tobacco company a case of gamekeeper turned poacher – or is there another interpretation we can put on it?
So much attention is given to the edicts of the US Food and Drug Administration (FDA) that it’s easy to forget individual states – not to mention cities – can also have a big impact on the regulation of novel nicotine products
Could the involvement of Snoop Dogg help a Californian company to “disrupt tobacco’s nearly $1tn industry with hemp cigarettes, smoking paper and other alternatives to nicotine tobacco”?
Flavours continue to be the main target of the Food and Drug Administration (FDA) in the US when it comes to novel nicotine products, it seems – and that could give heated tobacco an edge over e-cigarettes
There remains a worryingly large amount of research on novel nicotine products which makes casual, almost always negative, assumptions…and the occasional item so faulty it should never have been published at all
Correlation is not causation, but it’s tempting to see a meaningful pattern in figures showing that US adults (particularly the younger ones) are smoking less tobacco and using more cannabis
It’s fascinating to speculate on how the pouch market will develop. Who will use them, and why, and what will they replace?
After the victory of right-wing parties in Sweden’s very close election this week, the country’s tobacco alternatives sector – and its customers – may well be breathing a sigh of relief
Another day, another judgement in the saga of the US vapour industry’s cases against the Food and Drug Administration (FDA) – but what might the conflicting decisions mean for other smoking alternatives?
Scientific research into novel nicotine alternatives has so far largely focused on vaping, but that is likely to change as the products become more widespread
You can almost hear the judge’s sigh as he wrote his latest opinion in the long-running litigation between the FDA and the cigar industry over the latter’s treatment by the 2016 final deeming rule. Here we go again…
Could the Khan report, which endorses the UK’s positive attitude towards e-cigs also have lessons for the rest of the world, even for countries where there is far more hostility toward novel tobacco products?
Some headlines notwithstanding, it doesn’t sound like Joe Biden actually sat in the Oval Office and signed off mandatory nicotine reduction while photographers recorded the historic moment
Rumours circulating this week that the Biden administration is about to put its weight behind mandatory nicotine reduction in combustibles will have been music to the ears of 22nd Century Group, if few others
Most tobacco companies are keen to be seen supporting the concept of harm reduction, especially through reduced-risk products like e-cigarettes, heat-not-burn and pouches. But how far is their support for the idea actually having an effect on their activities right now, as well as their future direction?
Speaking at the launch of the seventh edition of the Atlas, US public health scholar Jeffrey Drope suggested that new nicotine technologies are “a huge distraction” which have “confused governments, the public health community and the public”
The $16bn takeover of Swedish Match by Philip Morris International (PMI) now seems more likely to happen than not (at least as of today; these things are never certain until the last signature is signed)
The long-mooted proposal to prohibit menthol is the most dramatic step the US Food and Drug Administration (FDA) has taken since the 2009 Tobacco Control Act exempted menthol from a general ban on flavoured tobacco
What will Michele Mital’s reign as acting director of the US Food and Drug Administration (FDA) Center for Tobacco Products (CTP) mean in terms of policy?
Michele Mital’s appointment as acting head of the Center for Tobacco Products (CTP) is not bad news for the industry, even if it’s not quite good news. And there may be bigger change at the Centers for Disease Control and Prevention (CDC)
A no-doubt well-meaning ballot measure enthusiastically taken up by voters just 18 months ago now has General Assembly members in the US state of Colorado tied up in a knot of their own making
The Society for Research on Nicotine and Tobacco (SRNT) published a huge number of research abstracts to accompany its annual get-together – here are some of the highlights
Acceptance by the US FDA of very-low-nicotine cigarettes as a modified risk product may be controversial, even bizarre, but it will be worth seeing how they perform in the market – and how that may affect future regulation of alternatives
The heated tobacco sector has, compared with its cousin vapour, always suffered from a lack of scientific research and from the perception that most of what does exist is industry-funded
Robert Califf’s expected return to head the US FDA has excited plenty of attention in the world of e-cigarettes, but there’s been much less talk about the likely impact on heated tobacco, pouches and other novel nicotine products
While the decision to give marketing authorisation to some RJ Reynolds relates specifically to e-cigarette products, it’s highly likely that much the same priorities will govern official thinking on other alternative products
Some light is now dawning on some truths long since suspected about the US Food and Drug Administration (FDA)’s approach to tobacco-alternative products of all kinds through its cumbersome evaluation of e-cigarettes
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the TobaccoIntelligence team.
